about
Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab.Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.Epidemiology of inhibitors and current treatment strategies.Long-term aspects of hemophilia B treatment: part I-role for prophylaxis.Role of von Willebrand factor in immune tolerance induction.Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?A review of immune tolerance induction with Haemate P in haemophilia A.Inhibitors in patients with haemophilia A.Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.Factor VIII products and inhibitor development in severe hemophilia A.Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations?Epidemiology of inhibitors in haemophilia A.When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.Delayed diagnosis of hereditary angioedema: Thirty-nine years of inadequate treatment.Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study.Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.Prevention of joint damage in hemophilic children with early prophylaxis.Successful management of hereditary angioedema during pregnancy in a patient with heterozygous MTHFR mutation.Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys.Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease.The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports.Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy.Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series.Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis.Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.Immune tolerance induction: What have we learned over time?
P50
Q33361834-f7c2fdc9-41e9-d927-242c-ec8bc273cfecQ33755932-c334bba3-4c45-49e1-e9c3-813cc6dc3252Q35162612-f4686289-49ab-eccd-4306-e29084d2154bQ35867951-9b918eb3-4581-daaa-dedb-d3c4c1ea0519Q36105376-9f4c22ae-412d-ee1f-e095-b00023d85c6cQ36661804-9bb61aaa-4832-97f3-38e6-a4fc07bf1910Q36661863-ed1c8126-4807-c85a-d69f-41b2fcdc5b30Q37185097-5b024d88-42a3-b263-d1bc-5845d792b029Q38070813-f0987dfe-4033-c6eb-ae51-086d750647a5Q38156000-c0f0562f-4de4-cc87-5da1-891b82e7b497Q38205515-c3989ac6-4939-f54d-1116-c5d2ab0b6019Q38282775-e2fefc7f-4ca5-7f05-1bf5-ce1faa9b5be7Q38325328-593b406a-4947-d3cb-7b80-bfb791a4aee5Q38739383-5a1d3656-4ea2-d8b5-2ee9-47adf1cfa211Q43535398-305817b1-4e39-87b0-5c1a-ed6bd1c0fd96Q43770114-c5a82ec8-485d-accc-a3dd-c7047735e9b0Q44302617-45a1380c-491f-2c45-4e53-88d34cdecb5dQ44905435-a2654b98-43b5-518f-f7e8-0196c7f201b3Q45854909-eebc84cb-46ae-9b7a-c167-8a0bf29d6d39Q45855813-98a94502-45b8-400b-b9f0-f20bddc4dd4cQ45857979-0192b778-4e45-ca7d-0179-b5a5355235f0Q45861990-84ab7faa-4363-1a31-5c5f-74b1ebf14144Q45862449-b2377cc4-4264-7593-944a-9837f39579bdQ45865024-a5d86631-4f99-e423-3b78-95617b6077c7Q45865210-e241dc86-433e-ebc6-c3a0-bfaab82dcd92Q45867304-651cba17-4ce1-e577-8465-daf8487c4213Q45869230-da29f513-4d8b-f8d9-2088-b787ec3e7952Q45870696-3ab36e3f-4562-0bf0-5b65-77c1980d1989Q45877796-356cf7b8-42d3-a6b3-8354-ec0858c658fbQ45877949-7bd26a0c-4189-6d0c-22c8-b5fda0ce6b72Q45883527-c39787b1-42a0-3a0c-87b7-a2cf2da96b45Q45884109-67ca81ec-44f8-5943-c8c3-ebc6acd5e3edQ45884849-989703dc-4c54-336a-1130-10dd783430daQ45885112-94bc8b97-4a73-2730-31c7-e0c0033b4274Q45886277-36ee73cf-4e06-b77e-10af-23c0686cfec5Q45889401-50cf17dc-4016-db86-efb6-8e9c3ca14d0bQ45890206-f590cc15-46bd-090c-3ba7-1a321b57109dQ50048445-bd58d982-4a0c-4ede-47e9-8e9bd32e42b4Q50968397-31e0f334-4c24-357f-bb14-aaaf4643a0a2Q52354532-3f148e44-4574-f57f-6d00-ff0899966e42
P50
description
Haematologist, Haemophilia Centre Rhein Main (HZRM)
@en
Hämatologe, Hämophilie Zentrum Rhein Main (HZRM)
@de
hematolog
@sv
hematoloog
@nl
hematólogo
@es
hématologue
@fr
name
Carmen Escuriola Ettingshausen
@de
Carmen Escuriola Ettingshausen
@en
Carmen Escuriola Ettingshausen
@es
Carmen Escuriola Ettingshausen
@fr
Carmen Escuriola Ettingshausen
@ig
Carmen Escuriola Ettingshausen
@nl
Carmen Escuriola Ettingshausen
@sv
Carmen Escuriola Ettingshausen
@sw
type
label
Carmen Escuriola Ettingshausen
@de
Carmen Escuriola Ettingshausen
@en
Carmen Escuriola Ettingshausen
@es
Carmen Escuriola Ettingshausen
@fr
Carmen Escuriola Ettingshausen
@ig
Carmen Escuriola Ettingshausen
@nl
Carmen Escuriola Ettingshausen
@sv
Carmen Escuriola Ettingshausen
@sw
altLabel
Carmen Ecuriola-Ettingshausen
@en
Carmen Escuriola
@en
Carmen Escuriola
@nl
Carmen Escuriola-Ettingshausen
@nl
prefLabel
Carmen Escuriola Ettingshausen
@de
Carmen Escuriola Ettingshausen
@en
Carmen Escuriola Ettingshausen
@es
Carmen Escuriola Ettingshausen
@fr
Carmen Escuriola Ettingshausen
@ig
Carmen Escuriola Ettingshausen
@nl
Carmen Escuriola Ettingshausen
@sv
Carmen Escuriola Ettingshausen
@sw
P214
P227
P106
P21
P213
0000 0000 1359 825X
P214
P227
P31
P4012
P569
1965-01-01T00:00:00Z